UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) announced the successful completion of the primary endpoint in a Phase III trial for its anti-PD-L1 drug Imfinzi (durvalumab). The trial investigated the combination of Imfinzi with bevacizumab, originally developed by Roche (SWX: ROG) as Avastin, and transarterial chemoembolization (TACE) for embolization-eligible hepatocellular carcinoma (HCC). The results indicated that this intervention reduced the risk of disease progression or death by 23%, increasing median progression-free survival (PFS) from 8.2 months to 15 months compared to TACE alone.
Additionally, the treatment combo increased the secondary endpoint of time to progression (TTP) to 22 months from 10 months with TACE. The safety profile of the combination was found to be consistent with those of Imfinzi and bevacizumab. The study is ongoing to further evaluate the key secondary endpoint of overall survival (OS).- Flcube.com
